 |
|
|
|
| Plan Name | FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT |
| Plan identification number | 263 |
| Company Name: | TRANSAMERICA LIFE INSURANCE COMPANY |
| Employer identification number (EIN): | 390989781 |
| NAIC Classification: | 524140 |
Additional information about TRANSAMERICA LIFE INSURANCE COMPANY
| Jurisdiction of Incorporation: | Iowa Secretary of State Business Entities |
| Incorporation Date: | 1976-06-30 |
| Company Identification Number: | 069666 |
| Legal Registered Office Address: |
6400 C ST SW CEDAR RAPIDS United States of America (USA) 52499 |
More information about TRANSAMERICA LIFE INSURANCE COMPANY
| Plan id# | Filing Submission Date | Name of Administrator | Date Administrator Signed | Name of Company Sponsor | Date Sponsor Signed |
|---|---|---|---|---|---|
| 263 | 2023-01-01 | ||||
| 263 | 2022-01-01 | ||||
| 263 | 2021-01-01 | ||||
| 263 | 2020-01-01 | ||||
| 263 | 2019-01-01 | ||||
| 263 | 2018-01-01 | ||||
| 263 | 2017-01-01 | 2018-10-04 | |||
| 263 | 2016-01-01 | 2017-10-04 | |||
| 263 | 2015-01-01 | 2016-09-22 | |||
| 263 | 2014-01-01 | 2015-10-09 | |||
| 263 | 2014-01-01 | 2015-12-04 | |||
| 263 | 2013-01-01 | 2014-07-10 | |||
| 263 | 2012-01-01 | 2013-09-11 | |||
| 263 | 2011-01-01 | 2012-09-13 | |||
| 263 | 2010-01-01 | 2011-10-10 | |||
| 263 | 2009-01-01 | 2010-09-23 |
| Measure | Date | Value |
|---|---|---|
| 2023 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2023 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2023-12-31 | $153,555 |
| Total unrealized appreciation/depreciation of assets | 2023-12-31 | $153,555 |
| Total transfer of assets to this plan | 2023-12-31 | $81,510 |
| Total transfer of assets from this plan | 2023-12-31 | $336,085 |
| Total income from all sources (including contributions) | 2023-12-31 | $153,555 |
| Total of all expenses incurred | 2023-12-31 | $2,227 |
| Value of total assets at end of year | 2023-12-31 | $956,907 |
| Value of total assets at beginning of year | 2023-12-31 | $1,060,154 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2023-12-31 | $2,227 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2023-12-31 | $1 |
| Value of net income/loss | 2023-12-31 | $151,328 |
| Value of net assets at end of year (total assets less liabilities) | 2023-12-31 | $956,907 |
| Value of net assets at beginning of year (total assets less liabilities) | 2023-12-31 | $1,060,154 |
| Investment advisory and management fees | 2023-12-31 | $2,227 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2023-12-31 | $956,906 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2023-12-31 | $1,060,154 |
| Unrealized appreciation/depreciation of other (non real estate) assets | 2023-01-01 | $153,555 |
| Total unrealized appreciation/depreciation of assets | 2023-01-01 | $153,555 |
| Total transfer of assets to this plan | 2023-01-01 | $81,510 |
| Total transfer of assets from this plan | 2023-01-01 | $336,085 |
| Total income from all sources (including contributions) | 2023-01-01 | $153,555 |
| Total of all expenses incurred | 2023-01-01 | $2,227 |
| Value of total assets at end of year | 2023-01-01 | $956,907 |
| Value of total assets at beginning of year | 2023-01-01 | $1,060,154 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2023-01-01 | $2,227 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2023-01-01 | $1 |
| Value of net income/loss | 2023-01-01 | $151,328 |
| Value of net assets at end of year (total assets less liabilities) | 2023-01-01 | $956,907 |
| Value of net assets at beginning of year (total assets less liabilities) | 2023-01-01 | $1,060,154 |
| Investment advisory and management fees | 2023-01-01 | $2,227 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2023-01-01 | $956,906 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2023-01-01 | $1,060,154 |
| 2022 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2022 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2022-12-31 | $-139,436 |
| Total unrealized appreciation/depreciation of assets | 2022-12-31 | $-139,436 |
| Total transfer of assets to this plan | 2022-12-31 | $239,208 |
| Total transfer of assets from this plan | 2022-12-31 | $161,516 |
| Total income from all sources (including contributions) | 2022-12-31 | $-138,041 |
| Total of all expenses incurred | 2022-12-31 | $2,363 |
| Value of total assets at end of year | 2022-12-31 | $1,060,154 |
| Value of total assets at beginning of year | 2022-12-31 | $1,122,866 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2022-12-31 | $2,363 |
| Total dividends received (eg from common stock, registered investment company shares) | 2022-12-31 | $1,395 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2022-12-31 | $1 |
| Value of net income/loss | 2022-12-31 | $-140,404 |
| Value of net assets at end of year (total assets less liabilities) | 2022-12-31 | $1,060,154 |
| Value of net assets at beginning of year (total assets less liabilities) | 2022-12-31 | $1,122,866 |
| Investment advisory and management fees | 2022-12-31 | $2,363 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2022-12-31 | $1,060,154 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2022-12-31 | $1,122,865 |
| Income. Dividends from common stock | 2022-12-31 | $1,395 |
| Unrealized appreciation/depreciation of other (non real estate) assets | 2022-01-01 | $-139,436 |
| Total unrealized appreciation/depreciation of assets | 2022-01-01 | $-139,436 |
| Total transfer of assets to this plan | 2022-01-01 | $239,208 |
| Total transfer of assets from this plan | 2022-01-01 | $161,516 |
| Total income from all sources (including contributions) | 2022-01-01 | $-138,041 |
| Total of all expenses incurred | 2022-01-01 | $2,363 |
| Value of total assets at end of year | 2022-01-01 | $1,060,154 |
| Value of total assets at beginning of year | 2022-01-01 | $1,122,866 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2022-01-01 | $2,363 |
| Total dividends received (eg from common stock, registered investment company shares) | 2022-01-01 | $1,395 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2022-01-01 | $1 |
| Value of net income/loss | 2022-01-01 | $-140,404 |
| Value of net assets at end of year (total assets less liabilities) | 2022-01-01 | $1,060,154 |
| Value of net assets at beginning of year (total assets less liabilities) | 2022-01-01 | $1,122,866 |
| Investment advisory and management fees | 2022-01-01 | $2,363 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2022-01-01 | $1,060,154 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2022-01-01 | $1,122,865 |
| Income. Dividends from common stock | 2022-01-01 | $1,395 |
| 2021 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2021 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2021-12-31 | $-426,198 |
| Total unrealized appreciation/depreciation of assets | 2021-12-31 | $-426,198 |
| Total transfer of assets to this plan | 2021-12-31 | $411,199 |
| Total transfer of assets from this plan | 2021-12-31 | $1,273,905 |
| Total income from all sources (including contributions) | 2021-12-31 | $-288,556 |
| Total of all expenses incurred | 2021-12-31 | $4,004 |
| Value of total assets at end of year | 2021-12-31 | $1,122,866 |
| Value of total assets at beginning of year | 2021-12-31 | $2,278,132 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2021-12-31 | $4,004 |
| Total dividends received (eg from common stock, registered investment company shares) | 2021-12-31 | $7,869 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2021-12-31 | $1 |
| Value of net income/loss | 2021-12-31 | $-292,560 |
| Value of net assets at end of year (total assets less liabilities) | 2021-12-31 | $1,122,866 |
| Value of net assets at beginning of year (total assets less liabilities) | 2021-12-31 | $2,278,132 |
| Investment advisory and management fees | 2021-12-31 | $4,004 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2021-12-31 | $1,122,865 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2021-12-31 | $2,278,132 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2021-12-31 | $129,773 |
| Income. Dividends from common stock | 2021-12-31 | $7,869 |
| 2020 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2020 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2020-12-31 | $266,243 |
| Total unrealized appreciation/depreciation of assets | 2020-12-31 | $266,243 |
| Total transfer of assets to this plan | 2020-12-31 | $790,600 |
| Total transfer of assets from this plan | 2020-12-31 | $2,469,562 |
| Total income from all sources (including contributions) | 2020-12-31 | $587,553 |
| Total of all expenses incurred | 2020-12-31 | $6,248 |
| Value of total assets at end of year | 2020-12-31 | $2,278,132 |
| Value of total assets at beginning of year | 2020-12-31 | $3,375,789 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2020-12-31 | $6,248 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2020-12-31 | $1 |
| Value of net income/loss | 2020-12-31 | $581,305 |
| Value of net assets at end of year (total assets less liabilities) | 2020-12-31 | $2,278,132 |
| Value of net assets at beginning of year (total assets less liabilities) | 2020-12-31 | $3,375,789 |
| Investment advisory and management fees | 2020-12-31 | $6,248 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2020-12-31 | $2,278,132 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2020-12-31 | $3,375,788 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2020-12-31 | $321,310 |
| 2019 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2019 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2019-12-31 | $660,606 |
| Total unrealized appreciation/depreciation of assets | 2019-12-31 | $660,606 |
| Total transfer of assets to this plan | 2019-12-31 | $547,273 |
| Total transfer of assets from this plan | 2019-12-31 | $1,445,340 |
| Total income from all sources (including contributions) | 2019-12-31 | $954,973 |
| Total of all expenses incurred | 2019-12-31 | $8,911 |
| Value of total assets at end of year | 2019-12-31 | $3,375,789 |
| Value of total assets at beginning of year | 2019-12-31 | $3,327,794 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2019-12-31 | $8,911 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2019-12-31 | $1 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2019-12-31 | $1 |
| Value of net income/loss | 2019-12-31 | $946,062 |
| Value of net assets at end of year (total assets less liabilities) | 2019-12-31 | $3,375,789 |
| Value of net assets at beginning of year (total assets less liabilities) | 2019-12-31 | $3,327,794 |
| Investment advisory and management fees | 2019-12-31 | $8,911 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2019-12-31 | $3,375,788 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2019-12-31 | $3,327,793 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2019-12-31 | $294,367 |
| 2018 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2018 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2018-12-31 | $-638,366 |
| Total unrealized appreciation/depreciation of assets | 2018-12-31 | $-638,366 |
| Total transfer of assets to this plan | 2018-12-31 | $856,106 |
| Total transfer of assets from this plan | 2018-12-31 | $4,335,672 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2018-12-31 | $555 |
| Total income from all sources (including contributions) | 2018-12-31 | $-522,665 |
| Total of all expenses incurred | 2018-12-31 | $12,538 |
| Value of total assets at end of year | 2018-12-31 | $3,327,794 |
| Value of total assets at beginning of year | 2018-12-31 | $7,343,118 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2018-12-31 | $12,538 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2018-12-31 | $1 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2018-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2018-12-31 | $555 |
| Value of net income/loss | 2018-12-31 | $-535,203 |
| Value of net assets at end of year (total assets less liabilities) | 2018-12-31 | $3,327,794 |
| Value of net assets at beginning of year (total assets less liabilities) | 2018-12-31 | $7,342,563 |
| Investment advisory and management fees | 2018-12-31 | $12,538 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2018-12-31 | $3,327,793 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2018-12-31 | $7,343,118 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2018-12-31 | $115,701 |
| 2017 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2017 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2017-12-31 | $1,311,901 |
| Total unrealized appreciation/depreciation of assets | 2017-12-31 | $1,311,901 |
| Total transfer of assets to this plan | 2017-12-31 | $1,254,156 |
| Total transfer of assets from this plan | 2017-12-31 | $4,098,143 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2017-12-31 | $555 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2017-12-31 | $0 |
| Total income from all sources (including contributions) | 2017-12-31 | $1,484,050 |
| Total loss/gain on sale of assets | 2017-12-31 | $0 |
| Total of all expenses incurred | 2017-12-31 | $21,246 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2017-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2017-12-31 | $0 |
| Value of total assets at end of year | 2017-12-31 | $7,343,118 |
| Value of total assets at beginning of year | 2017-12-31 | $8,723,746 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2017-12-31 | $21,246 |
| Total interest from all sources | 2017-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2017-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2017-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2017-12-31 | $669 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2017-12-31 | $555 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2017-12-31 | $0 |
| Value of net income/loss | 2017-12-31 | $1,462,804 |
| Value of net assets at end of year (total assets less liabilities) | 2017-12-31 | $7,342,563 |
| Value of net assets at beginning of year (total assets less liabilities) | 2017-12-31 | $8,723,746 |
| Investment advisory and management fees | 2017-12-31 | $21,246 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2017-12-31 | $7,343,118 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2017-12-31 | $8,723,077 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2017-12-31 | $172,149 |
| Net investment gain/loss from pooled separate accounts | 2017-12-31 | $0 |
| Income. Dividends from common stock | 2017-12-31 | $0 |
| Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2017-12-31 | $0 |
| 2016 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2016 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2016-12-31 | $-3,138,691 |
| Total unrealized appreciation/depreciation of assets | 2016-12-31 | $-3,138,691 |
| Total transfer of assets to this plan | 2016-12-31 | $5,802,101 |
| Total transfer of assets from this plan | 2016-12-31 | $9,746,674 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2016-12-31 | $0 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2016-12-31 | $67,295 |
| Total income from all sources (including contributions) | 2016-12-31 | $-2,751,504 |
| Total loss/gain on sale of assets | 2016-12-31 | $0 |
| Total of all expenses incurred | 2016-12-31 | $26,371 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2016-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2016-12-31 | $0 |
| Value of total assets at end of year | 2016-12-31 | $8,723,746 |
| Value of total assets at beginning of year | 2016-12-31 | $15,513,489 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2016-12-31 | $26,371 |
| Total interest from all sources | 2016-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2016-12-31 | $112,816 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2016-12-31 | $669 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2016-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2016-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2016-12-31 | $67,295 |
| Value of net income/loss | 2016-12-31 | $-2,777,875 |
| Value of net assets at end of year (total assets less liabilities) | 2016-12-31 | $8,723,746 |
| Value of net assets at beginning of year (total assets less liabilities) | 2016-12-31 | $15,446,194 |
| Investment advisory and management fees | 2016-12-31 | $26,371 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2016-12-31 | $8,723,077 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2016-12-31 | $15,513,489 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2016-12-31 | $274,371 |
| Net investment gain/loss from pooled separate accounts | 2016-12-31 | $0 |
| Income. Dividends from common stock | 2016-12-31 | $112,816 |
| Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2016-12-31 | $0 |
| 2015 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2015 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2015-12-31 | $-911,698 |
| Total unrealized appreciation/depreciation of assets | 2015-12-31 | $-911,698 |
| Total transfer of assets to this plan | 2015-12-31 | $13,576,283 |
| Total transfer of assets from this plan | 2015-12-31 | $11,472,268 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2015-12-31 | $67,295 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2015-12-31 | $148,121 |
| Total income from all sources (including contributions) | 2015-12-31 | $283,946 |
| Total loss/gain on sale of assets | 2015-12-31 | $0 |
| Total of all expenses incurred | 2015-12-31 | $39,851 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2015-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2015-12-31 | $0 |
| Value of total assets at end of year | 2015-12-31 | $15,513,489 |
| Value of total assets at beginning of year | 2015-12-31 | $13,246,205 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2015-12-31 | $39,851 |
| Total interest from all sources | 2015-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2015-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2015-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2015-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2015-12-31 | $67,295 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2015-12-31 | $148,121 |
| Value of net income/loss | 2015-12-31 | $244,095 |
| Value of net assets at end of year (total assets less liabilities) | 2015-12-31 | $15,446,194 |
| Value of net assets at beginning of year (total assets less liabilities) | 2015-12-31 | $13,098,084 |
| Investment advisory and management fees | 2015-12-31 | $39,851 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2015-12-31 | $15,513,489 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2015-12-31 | $13,246,205 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2015-12-31 | $1,195,644 |
| Net investment gain/loss from pooled separate accounts | 2015-12-31 | $0 |
| Income. Dividends from common stock | 2015-12-31 | $0 |
| Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2015-12-31 | $0 |
| 2014 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2014 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2014-12-31 | $2,483,145 |
| Total unrealized appreciation/depreciation of assets | 2014-12-31 | $2,483,145 |
| Total transfer of assets to this plan | 2014-12-31 | $8,054,455 |
| Total transfer of assets from this plan | 2014-12-31 | $6,887,384 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2014-12-31 | $148,121 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2014-12-31 | $0 |
| Total income from all sources (including contributions) | 2014-12-31 | $2,986,250 |
| Total loss/gain on sale of assets | 2014-12-31 | $0 |
| Total of all expenses incurred | 2014-12-31 | $27,069 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2014-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2014-12-31 | $0 |
| Value of total assets at end of year | 2014-12-31 | $13,246,205 |
| Value of total assets at beginning of year | 2014-12-31 | $8,971,832 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2014-12-31 | $27,069 |
| Total interest from all sources | 2014-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2014-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2014-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2014-12-31 | $30,383 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2014-12-31 | $148,121 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2014-12-31 | $0 |
| Value of net income/loss | 2014-12-31 | $2,959,181 |
| Value of net assets at end of year (total assets less liabilities) | 2014-12-31 | $13,098,084 |
| Value of net assets at beginning of year (total assets less liabilities) | 2014-12-31 | $8,971,832 |
| Investment advisory and management fees | 2014-12-31 | $27,069 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2014-12-31 | $13,246,205 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2014-12-31 | $8,941,449 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2014-12-31 | $503,105 |
| Net investment gain/loss from pooled separate accounts | 2014-12-31 | $0 |
| Income. Dividends from common stock | 2014-12-31 | $0 |
| Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2014-12-31 | $0 |
| 2013 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2013 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2013-12-31 | $2,578,622 |
| Total unrealized appreciation/depreciation of assets | 2013-12-31 | $2,578,622 |
| Total transfer of assets to this plan | 2013-12-31 | $4,831,388 |
| Total transfer of assets from this plan | 2013-12-31 | $2,782,043 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2013-12-31 | $0 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2013-12-31 | $47,730 |
| Total income from all sources (including contributions) | 2013-12-31 | $3,130,356 |
| Total loss/gain on sale of assets | 2013-12-31 | $0 |
| Total of all expenses incurred | 2013-12-31 | $16,053 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2013-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2013-12-31 | $0 |
| Value of total assets at end of year | 2013-12-31 | $8,971,832 |
| Value of total assets at beginning of year | 2013-12-31 | $3,855,914 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2013-12-31 | $16,053 |
| Total interest from all sources | 2013-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2013-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2013-12-31 | $30,383 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2013-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2013-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2013-12-31 | $47,730 |
| Value of net income/loss | 2013-12-31 | $3,114,303 |
| Value of net assets at end of year (total assets less liabilities) | 2013-12-31 | $8,971,832 |
| Value of net assets at beginning of year (total assets less liabilities) | 2013-12-31 | $3,808,184 |
| Investment advisory and management fees | 2013-12-31 | $16,053 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2013-12-31 | $8,941,449 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2013-12-31 | $3,855,914 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2013-12-31 | $551,734 |
| Net investment gain/loss from pooled separate accounts | 2013-12-31 | $0 |
| Income. Dividends from common stock | 2013-12-31 | $0 |
| Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2013-12-31 | $0 |
| 2012 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2012 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2012-12-31 | $745,873 |
| Total unrealized appreciation/depreciation of assets | 2012-12-31 | $745,873 |
| Total transfer of assets to this plan | 2012-12-31 | $2,627,317 |
| Total transfer of assets from this plan | 2012-12-31 | $1,812,936 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2012-12-31 | $47,730 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2012-12-31 | $5,545 |
| Total income from all sources (including contributions) | 2012-12-31 | $749,111 |
| Total loss/gain on sale of assets | 2012-12-31 | $0 |
| Total of all expenses incurred | 2012-12-31 | $9,968 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2012-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2012-12-31 | $0 |
| Value of total assets at end of year | 2012-12-31 | $3,855,914 |
| Value of total assets at beginning of year | 2012-12-31 | $2,260,205 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2012-12-31 | $9,968 |
| Total interest from all sources | 2012-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2012-12-31 | $3,238 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2012-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2012-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2012-12-31 | $47,730 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2012-12-31 | $5,545 |
| Value of net income/loss | 2012-12-31 | $739,143 |
| Value of net assets at end of year (total assets less liabilities) | 2012-12-31 | $3,808,184 |
| Value of net assets at beginning of year (total assets less liabilities) | 2012-12-31 | $2,254,660 |
| Investment advisory and management fees | 2012-12-31 | $9,968 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2012-12-31 | $3,855,914 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2012-12-31 | $2,260,205 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2012-12-31 | $0 |
| Net investment gain/loss from pooled separate accounts | 2012-12-31 | $0 |
| Income. Dividends from common stock | 2012-12-31 | $3,238 |
| Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2012-12-31 | $0 |
| Opinion of an independent qualified public accountant for this plan | 2012-12-31 | Disclaimer |
| 2011 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2011 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2011-12-31 | $-175,347 |
| Total unrealized appreciation/depreciation of assets | 2011-12-31 | $-175,347 |
| Total transfer of assets to this plan | 2011-12-31 | $1,321,645 |
| Total transfer of assets from this plan | 2011-12-31 | $705,028 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2011-12-31 | $5,545 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2011-12-31 | $3,340 |
| Total income from all sources (including contributions) | 2011-12-31 | $126,311 |
| Total loss/gain on sale of assets | 2011-12-31 | $0 |
| Total of all expenses incurred | 2011-12-31 | $6,529 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2011-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2011-12-31 | $0 |
| Value of total assets at end of year | 2011-12-31 | $2,260,205 |
| Value of total assets at beginning of year | 2011-12-31 | $1,521,601 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2011-12-31 | $6,529 |
| Total interest from all sources | 2011-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2011-12-31 | $15,822 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2011-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2011-12-31 | $0 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2011-12-31 | $5,545 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2011-12-31 | $3,340 |
| Value of net income/loss | 2011-12-31 | $119,782 |
| Value of net assets at end of year (total assets less liabilities) | 2011-12-31 | $2,254,660 |
| Value of net assets at beginning of year (total assets less liabilities) | 2011-12-31 | $1,518,261 |
| Investment advisory and management fees | 2011-12-31 | $6,529 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2011-12-31 | $2,260,205 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2011-12-31 | $1,521,601 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2011-12-31 | $285,836 |
| Income. Dividends from common stock | 2011-12-31 | $15,822 |
| 2010 : FRANKLIN BIOTECHNOLOGY DISCOVERY RET OPT 2010 401k financial data | ||
| Unrealized appreciation/depreciation of other (non real estate) assets | 2010-12-31 | $143,740 |
| Total unrealized appreciation/depreciation of assets | 2010-12-31 | $143,740 |
| Total transfer of assets to this plan | 2010-12-31 | $1,438,601 |
| Total transfer of assets from this plan | 2010-12-31 | $280,063 |
| Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2010-12-31 | $3,340 |
| Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2010-12-31 | $0 |
| Total income from all sources (including contributions) | 2010-12-31 | $143,740 |
| Total loss/gain on sale of assets | 2010-12-31 | $0 |
| Total of all expenses incurred | 2010-12-31 | $3,154 |
| Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2010-12-31 | $0 |
| Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2010-12-31 | $0 |
| Value of total assets at end of year | 2010-12-31 | $1,521,601 |
| Value of total assets at beginning of year | 2010-12-31 | $219,137 |
| Total of administrative expenses incurred including professional, contract, advisory and management fees | 2010-12-31 | $3,154 |
| Total interest from all sources | 2010-12-31 | $0 |
| Total dividends received (eg from common stock, registered investment company shares) | 2010-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at end of year | 2010-12-31 | $0 |
| Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2010-12-31 | $31,254 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2010-12-31 | $3,340 |
| Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2010-12-31 | $0 |
| Value of net income/loss | 2010-12-31 | $140,586 |
| Value of net assets at end of year (total assets less liabilities) | 2010-12-31 | $1,518,261 |
| Value of net assets at beginning of year (total assets less liabilities) | 2010-12-31 | $219,137 |
| Investment advisory and management fees | 2010-12-31 | $3,154 |
| Value of interest in registered invesment companies (eg mutual funds) at end of year | 2010-12-31 | $1,521,601 |
| Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2010-12-31 | $187,883 |
| Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2010-12-31 | $0 |
| Income. Dividends from common stock | 2010-12-31 | $0 |
| If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. By linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. Please use the share buttons. It will only take a few seconds of your time. Thanks for helping | |
| | |
|